A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Ocrelizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms OPERA II; ORCHESTRA
  • Sponsors Roche
  • Most Recent Events

    • 15 Aug 2017 Health Canada has approved OCREVUS for RRMS. This approval is based on the pivotal OPERA I and II studies, according to a Roche media release.
    • 27 Jun 2017 Results of post hoc pooled analysis comparing efficacy of alemtuzumab and ocrelizumab based on number needed to treat (NNT) from CAMMS223,CARE-MS I, CARE-MS II and OPERA I and II studies,presented at the 3rd Congress of the European Academy of Neurology.
    • 27 Jun 2017 Results of exploratory analysis of the pooled intention-to-treat patient population from OPERA I and OPERA II studies, presented at the 3rd Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top